ADMA Biologics Faces Federal Securities Lawsuit Over Alleged Revenue Inflation
ADMA Biologics (NASDAQ:ADMA) is facing a federal securities lawsuit alleging revenue inflation through channel stuffing and concealment of distribution ties to an entity controlled by a senior executive. The case follows a short-seller report from Culper Research in March 2026, which triggered significant stock price declines.
Tickers: $ADMA
Topics: fraud_allegations legal revenue_inflation